Orchestra BioMed Holdings Inc
Research Orchestra BioMed Holdings Inc (OBIO) on Bullrun: market cap USD 322.16M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOBIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 322.16M
- Financial periodQ1 2026
- RevenueUSD 110.00K
- Net income-USD 20.69M
- Free cash flow-USD 22.35M
- Gross margin70.9%
Valuation Snapshot
latest market cap is USD 322.16M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 33.48M | -USD 52.70M | -USD 49.45M | 99.4% | -1.11 | USD 34.69M | USD 15.00M | USD 53.57M |
| FY2024 | USD 2.64M | -USD 61.02M | -USD 50.85M | 92.3% | -1.66 | USD 22.26M | USD 15.00M | USD 32.96M |
| FY2023 | USD 2.76M | -USD 49.12M | -USD 46.21M | 93.3% | -1.48 | USD 30.56M | USD 1.69M | USD 68.04M |
| FY2022 | USD 3.53M | -USD 33.61M | -USD 29.88M | 94.0% | -2.24 | USD 19.78M | USD 12.13M | USD 52.54M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 322.16M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 236.69M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 152.78M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 326.34M | n/a | n/a | n/a |
About Orchestra BioMed Holdings Inc
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Orchestra BioMed Holdings Inc's market cap?
Orchestra BioMed Holdings Inc's market capitalization is USD 322.16M.
What does Orchestra BioMed Holdings Inc do?
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.